Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?
Author(s): Kaisary AV, Iversen P, Tyrrell CJ, Carroll K, Morris T Affiliation(s): Royal Free Hospital, London, UK. Publication date & source: 2001, Prostate Cancer Prostatic Dis., 4(4):196-203. Publication type: Castration is the most widely used form of androgen ablation employed in the treatment of metastatic (M1) prostate cancer. Non-steroidal antiandrogen monotherapy is a potential alternative treatment option for men for whom castration is unacceptable or not indicated. Of the three non-steroidal antiandrogens, bicalutamide (‘Casodex’), flutamide and nilutamide, only bicalutamide has been compared with castration in large, controlled, randomised, Phase III trials in M1 patients. A post-hoc analysis of these studies indicated that bicalutamide 150 mg/day monotherapy may be of benefit to M1 patients with a prostate specific antigen (PSA) level
Related Questions
- Should hormone therapy be continued in patients who develop hormone-resistant metastatic prostate cancer (HRPC)?
- Can high dose, intravenous Vitamin C prolong life for patients with metastatic prostate cancer?
- Should Bisphosphonates Be Used Routinely in Patients With Prostate Cancer Metastatic to Bone?
